Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Flaherty

Showing results (371-380 of 580) with videos related to

Pageof 58
Sort By:
Cancer Research|October 3, 2007
Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiationJohn P Plastaras, Seok-Hyun Kim, Yingqiu Y Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2007
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibodyRobert H Vonderheide, Keith T Flaherty, Magi Khalil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2009
Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancersErica L Carpenter, Rosemarie Mick, Andrew J Rech, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With TrametinibGeorgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.
Journal for Immunotherapy of Cancer|February 23, 2022
Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysisSiming Li, Xiaowen Wu, Xieqiao Yan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2006
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinomaMark J Ratain, Tim Eisen, Walter M Stadler, et al.
British Journal of Cancer|August 2, 2006
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysisT Eisen, T Ahmad, K T Flaherty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2016
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory MelanomaDanny N Khalil, Michael A Postow, Nageatte Ibrahim, et al.
Journal of Translational Medicine|January 7, 2021
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutationEster Simeone, Giosuè Scognamiglio, Mariaelena Capone, et al.
Cancer Medicine|July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation statusBenjamin Izar, William Sharfman, F Stephen Hodi, et al.
Pageof 58

Showing results (371-380 of 580) with videos related to

Sort By:
Pageof 58
Cancer Research|October 3, 2007
Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiationJohn P Plastaras, Seok-Hyun Kim, Yingqiu Y Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2007
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibodyRobert H Vonderheide, Keith T Flaherty, Magi Khalil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2009
Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancersErica L Carpenter, Rosemarie Mick, Andrew J Rech, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With TrametinibGeorgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.
Journal for Immunotherapy of Cancer|February 23, 2022
Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysisSiming Li, Xiaowen Wu, Xieqiao Yan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2006
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinomaMark J Ratain, Tim Eisen, Walter M Stadler, et al.
British Journal of Cancer|August 2, 2006
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysisT Eisen, T Ahmad, K T Flaherty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2016
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory MelanomaDanny N Khalil, Michael A Postow, Nageatte Ibrahim, et al.
Journal of Translational Medicine|January 7, 2021
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutationEster Simeone, Giosuè Scognamiglio, Mariaelena Capone, et al.
Cancer Medicine|July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation statusBenjamin Izar, William Sharfman, F Stephen Hodi, et al.
Pageof 58